JP2023542211A5 - - Google Patents
Info
- Publication number
- JP2023542211A5 JP2023542211A5 JP2023518391A JP2023518391A JP2023542211A5 JP 2023542211 A5 JP2023542211 A5 JP 2023542211A5 JP 2023518391 A JP2023518391 A JP 2023518391A JP 2023518391 A JP2023518391 A JP 2023518391A JP 2023542211 A5 JP2023542211 A5 JP 2023542211A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- composition
- combination according
- disorder
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063080925P | 2020-09-21 | 2020-09-21 | |
| US63/080,925 | 2020-09-21 | ||
| US202063121152P | 2020-12-03 | 2020-12-03 | |
| US63/121,152 | 2020-12-03 | ||
| US202163139410P | 2021-01-20 | 2021-01-20 | |
| US63/139,410 | 2021-01-20 | ||
| US202163140440P | 2021-01-22 | 2021-01-22 | |
| US63/140,440 | 2021-01-22 | ||
| US202163180407P | 2021-04-27 | 2021-04-27 | |
| US63/180,407 | 2021-04-27 | ||
| PCT/US2021/071534 WO2022061378A2 (en) | 2020-09-21 | 2021-09-21 | Methods for treating neurological disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542211A JP2023542211A (ja) | 2023-10-05 |
| JP2023542211A5 true JP2023542211A5 (https=) | 2024-08-22 |
Family
ID=80776430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518391A Pending JP2023542211A (ja) | 2020-09-21 | 2021-09-21 | 神経疾患を処置するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230365963A1 (https=) |
| EP (1) | EP4213891A4 (https=) |
| JP (1) | JP2023542211A (https=) |
| AU (1) | AU2021344607A1 (https=) |
| CA (1) | CA3193406A1 (https=) |
| IL (1) | IL301525A (https=) |
| WO (1) | WO2022061378A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4314296A2 (en) | 2021-03-29 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| EP4423272A2 (en) * | 2021-10-29 | 2024-09-04 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| JP2025503910A (ja) * | 2022-01-27 | 2025-02-06 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 神経疾患を処置するための組成物 |
| WO2023212521A2 (en) * | 2022-04-25 | 2023-11-02 | Myrtelle Inc. | Treatments of disorders of myelin |
| EP4601743A1 (en) * | 2022-10-14 | 2025-08-20 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies |
| WO2024149844A1 (en) * | 2023-01-12 | 2024-07-18 | Nantes Université | Chemically-modified adeno-associated virus |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003288231A1 (en) * | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| EP2187898B8 (en) * | 2007-09-12 | 2016-09-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease |
| US8900627B2 (en) | 2008-06-06 | 2014-12-02 | Mirna Therapeutics, Inc. | Compositions for the in vivo delivery of RNAi agents |
| US9132173B2 (en) * | 2010-10-15 | 2015-09-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease |
| KR101367568B1 (ko) * | 2011-05-31 | 2014-02-27 | 임우석 | Ａｂｃ 수송체 조절을 통한 퇴행성신경질환에서 이상단백질 조절 |
| BR112014006596A2 (pt) | 2011-09-21 | 2017-03-28 | Yissum Res Dev Co | nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas |
| ES2661236T3 (es) | 2011-12-13 | 2018-03-28 | Henry Ford Health System | Procedimientos, sistemas y composiciones para administración de microARN derivado de células/a base de vesículas |
| KR102423442B1 (ko) * | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| US10457940B2 (en) * | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| KR20180063954A (ko) * | 2016-12-02 | 2018-06-14 | 서울대학교산학협력단 | 알츠하이머병 치료를 위한 마이크로RNA-188-5p의 용도 |
| WO2019177550A1 (en) | 2018-03-10 | 2019-09-19 | Koc Universitesi | Therapeutic nanoparticles containing argonaute for microrna delivery and compositions and methods using same |
| US20200071699A1 (en) * | 2018-08-31 | 2020-03-05 | Ghassan S. Kassab | Treatment of alzheimers disease with micro rna and ghrelin |
| US20220054597A1 (en) * | 2018-10-29 | 2022-02-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis |
-
2021
- 2021-09-21 EP EP21870467.4A patent/EP4213891A4/en active Pending
- 2021-09-21 US US18/027,293 patent/US20230365963A1/en active Pending
- 2021-09-21 WO PCT/US2021/071534 patent/WO2022061378A2/en not_active Ceased
- 2021-09-21 JP JP2023518391A patent/JP2023542211A/ja active Pending
- 2021-09-21 IL IL301525A patent/IL301525A/en unknown
- 2021-09-21 CA CA3193406A patent/CA3193406A1/en active Pending
- 2021-09-21 AU AU2021344607A patent/AU2021344607A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023542211A5 (https=) | ||
| US20250161485A1 (en) | Aav capsid variants and uses thereof | |
| KR20240113624A (ko) | Aav 캡시드 변이체 및 이의 용도 | |
| KR20250025387A (ko) | Aav 캡시드 변이체 및 이의 용도 | |
| JP7616995B2 (ja) | 神経変性疾患のための遺伝子治療 | |
| WO2019084068A1 (en) | GENE THERAPIES FOR NEURODEGENERATIVE DISEASE | |
| IL308514B1 (en) | Aav treatment of huntington's disease | |
| JP2021522836A5 (https=) | ||
| CN115279421A (zh) | 用于联合疗法的病毒载体 | |
| EP4547690A1 (en) | Aav capsid variants and uses thereof | |
| WO2025038430A1 (en) | Aav capsid variants and uses thereof | |
| WO2024226790A1 (en) | Aav capsid variants and uses thereof | |
| JP7854125B2 (ja) | 新規なデュアルヘルパープラスミド | |
| US20200283800A1 (en) | Gene therapies for neurodegenerative diseases | |
| JP2022548270A5 (https=) | ||
| CN113631706A (zh) | 用于治疗眼咽肌营养不良(opmd)的组合物和方法 | |
| JP2025503910A5 (https=) | ||
| WO2024211376A2 (en) | Compositions and methods for treating cag repeat diseases | |
| KR102839699B1 (ko) | 부신척수신경병증의 치료를 위한 abcd1을 코딩하는 핵산 서열의 척추강내 전달 | |
| JP2025512709A5 (https=) | ||
| WO2023220719A2 (en) | Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting | |
| JP2025509262A5 (https=) | ||
| JP2023507741A5 (https=) | ||
| JP2022523320A5 (https=) | ||
| CA3219287C (en) | Dual helper plasmid |